Matching trials
35 results
- ABC-01Independent statistical analysis of ABC-01, a phase 1 study evaluating hydroxychloroquine with hormonal therapy in metastatic estrogen receptor-positive breast cancer progressing on hormonal therapy.
- APTIndependent statistical analysis of the APT phase 1/2 study of AP203 in patients with locally advanced or metastatic solid tumors, including trial design, endpoints, planned statistical methods, interpretation, and limitations.
- ARROWIndependent statistical analysis of the ARROW phase 1/2 trial of pralsetinib in participants with RET-altered non-small cell lung cancer, thyroid cancer, and other advanced solid tumors.
- BREEZEIndependent statistical analysis of the BREEZE phase 1 study of Treprostinil Inhalation Powder in subjects with pulmonary arterial hypertension currently using Tyvaso, including study design, endpoints, planned statistical methods, safety, and interpretation.
- CARTITUDE-1An independent statistical analysis of CARTITUDE-1, evaluating JNJ-68284528, a BCMA-directed CAR-T therapy in participants with relapsed or refractory multiple myeloma.
- CheckMate-040An independent statistical analysis of CheckMate-040, a phase 1/2 non-randomized study of nivolumab and nivolumab-based combinations in patients with advanced hepatocellular carcinoma, based on publicly reported ClinicalTrials.gov data.
- CheckMate-358Independent statistical analysis of CheckMate-358 (NCT02488759), including trial design, registered endpoints, safety results, statistical methodology, interpretation, and limitations.
- CHRYSALISA detailed statistical review of the phase 1 CHRYSALIS study of amivantamab in participants with advanced non-small cell lung cancer, covering trial design, registered endpoints, planned statistical analysis, and interpretation.
- COMPARE-ACUTEIndependent statistical analysis of the randomized crossover COMPARE-ACUTE phase 1 study of dihydroergotamine mesylate and placebo on pulmonary arterial systolic pressure in healthy participants.
- DESTINY-Breast07Independent statistical analysis of DESTINY-Breast07, a phase 1/2 randomized study of trastuzumab deruxtecan combinations in HER2-positive metastatic breast cancer, including trial design, registered endpoints, planned statistical analysis, and interpretation.
- DESTINY-Lung03An independent statistical analysis of DESTINY-Lung03, a randomized phase Ib study evaluating the safety of T-DXd and immunotherapy agents with and without chemotherapy in advanced or metastatic HER2+, non-squamous NSCLC.
- DUET-2A statistical review of the phase 1 DUET-2 study of XmAb20717 in subjects with selected advanced solid tumors, including trial design, the registry-defined safety endpoint, planned statistical analysis, and interpretation of the…
- EBL06Independent statistical analysis and educational interpretation of the randomized phase 1 EBL06 trial evaluating a short-interval prime-boost Ebola vaccination strategy.
- FAKTIONIndependent statistical analysis of the FAKTION randomized phase 1/2 trial of fulvestrant with AZD5363 versus fulvestrant-based treatment in estrogen receptor positive breast cancer. Includes trial design, endpoints, planned statistical analysis, and interpretation…
- FOCUS HFA detailed statistical analysis of the randomized phase 1 FOCUS HF trial evaluating intramyocardial injection of autologous bone-marrow stem cells via NOGA mapping in patients with ischemic cardiomyopathy, including its crossover design,…
- GALAXYComplete statistical analysis of the GALAXY phase 1/2 clinical trial evaluating targeted antibody-drug conjugates for HER2 ultra-low or no expression advanced breast cancer, including design, endpoints, statistical methodology, planned analyses, and interpretation.
- GATSBYA complete statistical analysis and educational interpretation of the GATSBY phase 1/2 trial of gevokizumab for scleritis, including its single-group design, ordinal scleral inflammation endpoint, planned statistical approach, and reported safety.
- IPATunity150Independent statistical analysis of IPATunity150, evaluating ipatasertib plus palbociclib and fulvestrant versus placebo plus palbociclib and fulvestrant in hormone receptor positive and HER2 negative locally advanced unresectable or metastatic breast cancer.
- KEYNOTE-001An independent statistical analysis of KEYNOTE-001 (NCT01295827), covering its randomized phase 1 design, binary primary endpoints, dose-limiting toxicity, adverse events, overall response rate, statistical methodology, and interpretation.
- KEYNOTE-012Independent statistical analysis of KEYNOTE-012, a phase 1 non-randomized study of pembrolizumab in participants with advanced solid tumors, including trial design, registered endpoints, safety results, planned statistical methods, and interpretation.
- KEYNOTE-021Independent statistical analysis of KEYNOTE-021 (NCT02039674), including randomized trial design, objective response rate, progression-free survival, overall survival, statistical methods, interpretation, and limitations.
- LIBRETTO-001Independent statistical analysis of LIBRETTO-001, evaluating selpercatinib in participants with advanced solid tumors, RET fusion-positive solid tumors, and medullary thyroid cancer, with emphasis on trial design, registered endpoints, and planned statistical interpretation.
- LUME-Lung 3Independent statistical analysis of LUME-Lung 3 (NCT01346540), a randomized phase 1 trial evaluating nintedanib added to gemcitabine/cisplatin in first-line NSCLC with squamous cell histology.
- NEON-1Independent statistical analysis of NEON-1, a phase 1 study of ALPN-202 in subjects with advanced malignancies, including trial design, endpoints, statistical methodology, and interpretation.
- NRG-GY017Independent statistical analysis of NRG-GY017, a randomized phase 1 trial evaluating atezolizumab before and/or with chemoradiotherapy in patients with node-positive cervical cancer.
- SAILComplete statistical analysis of the SAIL phase 1 study of sirolimus and hydroxychloroquine in women with lymphangioleiomyomatosis, including trial design, safety endpoints, statistical methodology, and interpretation of the posted safety data.
- SCOUTA detailed statistical analysis of the SCOUT phase 1/2 trial of larotrectinib in children with tumors harboring NTRK fusion, including trial design, endpoints, planned analysis, statistical methodology, interpretation, and limitations.
- SEASONIndependent statistical analysis of the SEASON trial evaluating the safety, tolerability, and immunogenicity of motavizumab after dosing for a second season in children.
- STARTRK-1Independent statistical analysis of STARTRK-1, a phase 1 study of entrectinib in adult patients with locally advanced or metastatic solid tumors with NTRK1, NTRK2, NTRK3, ROS1, or ALK molecular alterations.
- STARTRK-NGIndependent statistical analysis of STARTRK-NG (NCT02650401), a phase 1/2 study of entrectinib in children and adolescents with locally advanced or metastatic solid tumors and CNS tumors.
- STOMPIndependent statistical analysis of STOMP (NCT02343042), a randomized phase 1/2 study evaluating selinexor with backbone treatments in patients with multiple myeloma, including dose-escalation, pharmacokinetic, response, and duration-of-response endpoints.
- TATTONIndependent statistical analysis of the phase 1 TATTON trial of AZD9291 in combination with AZD6094 or selumetinib in advanced non-small-cell lung cancer, including trial design, safety endpoints, planned analysis, and statistical interpretation.
- TRANSCEND NHL 001An independent statistical analysis of TRANSCEND NHL 001 (NCT02631044), evaluating JCAR017 single-dose and 2-dose schedules in B-cell non-Hodgkin lymphoma, with emphasis on safety, dose-limiting toxicity, and objective response rate.
- TRINITI-1An independent statistical analysis of TRINITI-1, evaluating ribociclib with everolimus and exemestane in HR+ HER2- locally advanced or metastatic breast cancer after progression on a CDK 4/6 inhibitor.
- ZUMA-1Independent statistical analysis of ZUMA-1 (NCT02348216), evaluating axicabtagene ciloleucel in adults with refractory or relapsed aggressive non-Hodgkin lymphoma. Includes trial design, registered endpoints, planned statistical methods, safety interpretation, limitations, and educational explanations.